Long-Term Outcomes After Hepatic and Pancreatic Resections for Metastases from Thyroid Cancer: a Systematic Review of the Literature
- 37 Downloads
The objective of our systematic review was to evaluate the long-term outcomes of surgical resection as a treatment strategy for liver and pancreatic metastases from thyroid cancer (TC).
A systematic search of three electronic databases for articles published up to October 2018 was conducted. All appropriate observational studies and case reports which reported outcomes from patients with TC metastatic to the liver or pancreas were considered eligible for inclusion in the present systematic review.
A total of 15 studies, which comprised of 16 patients that underwent hepatic or pancreatic resection for TC metastasis, were included in the present systematic review; among them, 5 presented with metastasis to the liver, whereas 11 had pancreatic metastatic disease. The median time interval between the initial thyroidectomy and the diagnosis of metastases (either hepatic or pancreatic) was 60 months (SE 23.8, 95% CI 13.3–106.7) for the entire cohort and the mean overall survival was 37.6 months (SE 8, 95% CI 22–53.3). Five patients with pancreatic metastases presented with recurrence whereas no recurrences were noted in patients with liver metastases.
Surgical resection of liver and pancreatic metastases from TC seems to be a safe and efficient treatment option for selected patients. In that setting, long-term outcomes in patients with resected TCLM are encouraging given the absence of recurrence as reported from the included studies, whereas in the case of TCPM, survival is limited due to advanced disease at diagnosis and recurrence rates.
KeywordsThyroid cancer Metastasis Liver Pancreas Survival
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 13.Ibarrola de Andres C, Castellano Megias VM, Ballestin Carcavilla C, Alberti Masgrau N, Perez Barrios A, De Agustin PA. Hepatic metastases from the spindle cell variant of medullary thyroid carcinoma: report of a case with diagnosis by fine needle aspiration biopsy. Acta Cytol. 2001;45:1022–6. https://doi.org/10.1159/000328348.CrossRefGoogle Scholar
- 15.Siddiqui AA, Olansky L, Sawh RN, Tierney WM. Pancreatic metastasis of tall cell variant of papillary thyroid carcinoma: diagnosis by endoscopic ultrasound-guided fine needle aspiration. JOP. 2006;7:417–22.Google Scholar
- 16.Meyer A, Behrend M. Is pancreatic resection justified for metastasis of papillary thyroid cancer? Anticancer Res. 2006;26:2269–73.Google Scholar
- 19.Besic N, Schwarzbartl-Pevec A, Vidergar-Kralj B, Crnic T, Gazic B, Marolt Music M. Treatment and outcome of 32 patients with distant metastases of Hurthle cell thyroid carcinoma: a single-institution experience. BMC Cancer. 2016;16(162):162. https://doi.org/10.1186/s12885-016-2179-3.CrossRefGoogle Scholar
- 25.Murakami Y, Shimura T, Okada R, Kofunato Y, Ishigame T, Yashima R, et al. Pancreatic metastasis of papillary thyroid carcinoma preoperatively diagnosed by endoscopic ultrasound-guided fine-needle aspiration biopsy: a case report with review of literatures. Clin J Gastroenterol. 2018;11:521–9. https://doi.org/10.1007/s12328-018-0875-z.CrossRefGoogle Scholar
- 27.Li XO, Li ZP, Wang P, Li CL, Wu JH, Zhang JZ, et al. Pancreatic metastasis of papillary thyroid carcinoma: a case report with review of the literature. Int J Clin Exp Pathol. 2014;7:819–22.Google Scholar
- 30.Alzahrani AS, AlQaraawi A, Al Sohaibani F, Almanea H, Abalkhail H. Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy. Thyroid. 2012;22:536–41. https://doi.org/10.1089/thy.2011.0247.CrossRefGoogle Scholar